Our decades of experience in large molecule drug development make Prolytix the “pro” customers can rely on to help accelerate their product’s development.
David Sunseri, Ph.D., is president and chief executive officer at Prolytix. He is responsible for leading the next phase of Prolytix’s growth, solidifying and expanding Prolytix’s position as a leading contract research organization (CRO) focused on large molecules and an innovator of biologic reagents and sample collection devices for research and diagnostic markets.
David served as CEO of PMI BioPharma Solutions, a specialty CDMO providing protein-based research, target validation, functional characterization, advanced assay development, and GMP manufacturing services. He led the company through a transition from pharmaceutical ownership to a private company focused on CRO and CDMO services until its sale to private equity in 2020.
Prior to PMI, David spent four years at Berg, LLC, in positions of increasing responsibility leading all aspects of CMC during this time. Most recently, he was the vice president, Product Development responsible for clinical trial manufacturing, engineering operations, supply chain, and formulations. Dave spent approximately 10 years with Schering-Plough and Merck in small molecule inhalation and parenteral development and commercial manufacturing of inhalation and medical device products.
David received his bachelor’s in chemistry from the University of North Alabama and Ph.D. in analytical chemistry, specializing in chromatography, from Florida State University under the direction of John G. Dorsey.
He serves on the University of North Alabama Foundation board of directors and is a member of the University of North Alabama’s College of Arts and Sciences advisory council.